Patent · US Active

Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5

US11155593B2 · kind B2 · utility

3Cited by

17References

12Claims

0Family size

Assignee

Silver Creek Pharmaceuticals, Inc. · US

Inventors

Laura D.J. Antipov · Oakland, US
Shawdee Eshghi · Oakland, US
Kristopher M. Kuchenbecker · San Francisco, US
Bjorn L. Millard · Orinda, US
Matthew Onsum · Corona, US
Andrea D. Nickerson · San Francisco, US
Timothy R. Stowe · San Francisco, US
Yan Zhang · San Francisco, US

Key dates

Filing date	Mar 17, 2020
Grant date	Oct 26, 2021
Priority date	—
Expiry date	Mar 17, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.